PR92618

TAIPEI, Oct. 27, 2021 /PRNewswire=KYODO JBN/ --

Medigen Vaccine Biologics Corp (MVC)(https://www.medigenvac.com/public/)

vaccine candidate, MVC-COV1901, has been recommended by an independent vaccine

prioritisation advisory group to be included in the World Health Organisation

(WHO) Solidarity Trial Vaccines (STv). Following the review of around 20

candidate vaccines by the external advisory group, MVC's vaccine was selected

as one of two to be included in the global trial.  

The announcement(https://www.who.int/news/item/26-10-2021-who-statement-on-solidarit

y-trial-vaccines) by WHO, comes after the approval from WHO Ethics Review

Committee and relevant regulatory authorities and ethics committees of

Colombia, Mali and Philippines granted approval for the study to progress. Each

clinical site and respective national principal investigators and research

teams have begun recruiting volunteers to join the trial.

This is an international, randomized clinical trial platform designed to

rapidly evaluate the efficacy and safety of promising new candidate vaccines

contributing to the creation of a larger portfolio of vaccines needed to

protect people from COVID-19 around the world.

MVC began developing its own vaccine in February of 2020 with the hopes of

bringing forth a solution capable of helping in part end the devastating

pandemic. MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen

adjuvanted with CpG 1018 supplied by Dynavax and aluminum hydroxide.

"We are extremely grateful that we have been selected to be part of the WHO

International Solidarity Trial Vaccines against COVID-19. We have been working

to design a vaccine that has mild side effects and actively protects the public

from the adverse effects of the virus. Seeing promising results thus far, we

hope that the international trial conducted by WHO and participating countries

will assist to curb the escalation of cases," said Charles Chen, Vice Chairman

& CEO, Medigen Vaccine Biologics Corp.

With the battle against the pandemic still on an incline, the need for

effective vaccines is still in high demand and MVC believes it has the

capacity, infrastructure, and expertise to contribute towards achieving global

protection.

About MVC-COV1901

MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with

CpG 1018(https://www.dynavax.com/science/cpg-1018/) supplied by

Dynavax(https://www.dynavax.com/) and aluminum hydroxide. The S-2P antigen is a

trimeric and prefusion-stable recombinant spike protein developed by the U.S.

NIH(https://www.niaid.nih.gov/). MVC has obtained a global technology license

for S-2P from the U.S. Vaccine Research Center at National Institutes of Health

(NIH).  Building upon the S-2P platform, MVC conducted large-scale screenings

of various adjuvants and finalized the compositions of MVC-COV1901 vaccine to

optimize safety and desired immunogenicity properties. MVC established the

production platform of MVC-COV1901 and based on MVC's preclinical, Phase 1 and

Phase 2 clinical study data, MVC-COV1901 has shown robust safety and promising

immunogenicity responses and as a result applied and was granted EUA in Taiwan

and continue to pursue global regulatory recognition.

About Medigen Vaccine Biologics Corp. (MVC)

MVC is a biopharmaceutical company using cell-based technologies to develop

novel vaccines and biosimilars. With a goal of national self-sufficiency, MVC

also aims to provide vaccines and biopharmaceuticals to meet regional needs and

with a desire to help globally against the threats of infectious diseases.

MVC's pipeline includes enterovirus EV71 vaccine, dengue vaccine, influenza

quadrivalent vaccine which all have entered late clinical stage. MVC's

large-scale production facility is state-of-the-art and adherent to

international PIC/s GMP requirements. For more information, visit

www.medigenvac.com.

WHO Media inquiries

mediainquiries@who.int

Medigen Contact:

Paul Torkehagen

Director, International Business Development

paul@medigenvac.com

Investor Relations:

ir@medigenvac.com

Medigen Media Enquiries:

Michelle Bridget, Continuum PR, on +6012-697-7356, or email

michelle.bridget@continuumpr.com  

SOURCE Medigen Vaccine Biologics Corporation